PREVENTIONGENETICS, LLC
MARSHFIELD, WI

PreventionGenetics, LLC, established in 2004, stands as a premier provider of germline DNA testing services. Located in Marshfield, Wisconsin, it offers the most extensive menu of genetic tests available in the United States. PreventionGenetics is known for its high-quality genomic testing, accredited by CLIA and ISO 15189:2012, surpassing regulatory requirements with an exemplary quality assurance record. Their sequencing error rate is impressively low at about one per 7 million nucleotides. PreventionGenetics focuses on reducing healthcare costs through effective utilization management strategies that save over $1.3 million annually for healthcare providers. This efficiency is achieved while providing advanced genetic testing and maintaining meticulous DNA data quality, which includes confirmatory procedures like Sanger sequencing for pathogenic or uncertain variants and gene-centric aCGH results validation via PCR. An innovative approach to patient care at PreventionGenetics involves retaining excess DNA from tests allowing easier future re-analyses and integration into electronic health records. They also support scientific research by sharing all their variant data with the NCBI ClinVar database, ensuring confidentiality is maintained. Leadership at PreventionGenetics includes Jerry Machado M.D., a certified molecular genetics lab director, focused on inherited cancer syndromes; Dr. Steiner, the Chief Medical Officer with extensive experience in medical genetics and research leadership; Angela Gruber Ph.D., who directs the Specimen Processing Department focusing on neuromuscular disorders; and Ben Dorshorst Ph.D., specializing in Hearing Loss and Deafness. Operating under Exact Sciences Corporation, PreventionGenetics is incorporated in Florida (File Number: M11000005535) but serves broadly across medical communities by offering clear pricing information online and free preventive medicine resources. Its continued contributions to the field of genetics, marked by its latest annual report on March 11, 2024, highlight its role as a leader in genetic testing and patient support services.